Boston, MA – [Insert Date] – Biogen is pushing forward with a pivotal Phase III registrational program for its novel anti-tau Alzheimer’s disease therapy, diranersen, a move that signals continued confidence in the drug’s potential despite its failure to meet the primary endpoint in a recent mid-stage clinical trial. While the drug did not demonstrate a significant dose-response for the key cognitive measure, early indicators of efficacy, particularly at lower doses, alongside promising biomarker data, have encouraged Biogen to proceed.
The decision to advance diranersen, an antisense oligonucleotide (ASO) developed by Ionis Pharmaceuticals and licensed by Biogen, comes after the completion of the Phase II CELIA trial (NCT05399888). This study investigated the efficacy and safety of diranersen in individuals experiencing mild cognitive impairment due to Alzheimer’s disease over a 76-week treatment period. Despite the missed primary endpoint, analysts and company executives are highlighting a confluence of secondary and exploratory data that they believe warrants further investigation in a larger, more definitive trial.
The CELIA Trial: A Nuanced Outcome
The Phase II CELIA trial aimed to evaluate diranersen’s impact on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score, a widely used measure of global cognitive and functional impairment in Alzheimer’s disease. Unfortunately, the trial did not achieve statistical significance in demonstrating a dose-response relationship for changes in CDR-SB scores after 76 weeks of treatment. This outcome, while a setback for achieving the trial’s primary objective, has been interpreted with a degree of nuance by industry observers and Biogen itself.
Crucially, a pre-specified analysis of cognitive endpoints revealed that all tested doses of diranersen showed a trend towards slowing clinical decline. Biogen has emphasized that this slowing of decline was particularly pronounced in patients receiving the lowest tested dose of 60mg administered every 24 weeks (Q6M). This finding, in particular, has become a cornerstone of Biogen’s rationale for advancing the drug.
Beyond cognitive assessments, the trial also incorporated advanced imaging techniques, including Positron Emission Tomography (PET) scans. These scans provided compelling biomarker data, indicating that diranersen effectively reduced tau levels in cerebrospinal fluid (CSF) and diminished the overall burden of tau pathology in the brain. Significantly, these beneficial effects on tau were sustained throughout the entire dosing period of the study, offering a potential biological mechanism for the observed clinical effects.
Safety Profile and Dosing Considerations
Regarding safety and tolerability, diranersen’s profile in the Phase II CELIA trial remained consistent with findings from earlier studies, including a Phase Ib trial. The incidence of adverse events (AEs) was generally comparable across all dose cohorts. However, it is noteworthy that a higher prevalence of serious adverse events (SAEs) was observed in the highest dose group. This observation underscores the importance of carefully selecting and optimizing dosing strategies for the upcoming Phase III trials, with a focus on maximizing efficacy while minimizing potential risks.
Biogen has indicated its intention to present detailed data from the Phase II CELIA trial at the upcoming 2026 Alzheimer’s Association International Conference (AAIC). This presentation will likely provide further insights into the specific safety and efficacy profiles observed across the different dose regimens and patient subgroups.
Analyst Perspectives and Market Reception
The mixed results of the CELIA trial have elicited a range of reactions from financial analysts who closely monitor the Alzheimer’s disease landscape. Citi analysts, for instance, have suggested that the miss on the primary endpoint "does not invalidate" the diranersen program. This perspective acknowledges the complexity of Alzheimer’s drug development and the potential for meaningful insights to emerge from secondary and exploratory analyses.
Similarly, analysts at William Blair have adopted a pragmatic view, stating that meeting the primary endpoint was not necessarily a "requisite for advancing development." Their cautious optimism stems from the observed slowing of cognitive decline across all doses, particularly the most favorable outcomes at the lowest dose. This sentiment is echoed by Philippa Salter, Managing Neurology Analyst at GlobalData, who, while describing the results as "disappointing," acknowledged the "silver lining" in Biogen’s confidence in the biomarker data and the slowing of cognitive decline.
However, the commercial landscape for Alzheimer’s therapies presents its own set of challenges. William Blair analysts have pointed to the underperformance of anti-amyloid therapies against commercial expectations, even those with similar efficacy profiles. They note that while anti-tau therapies may offer a distinct advantage by potentially avoiding some of the risks associated with anti-amyloid approaches, the path to market success remains demanding.
The Scientific Rationale: Targeting Tau in Alzheimer’s Disease
Diranersen, also known by its code name BIIB080, is a first-in-class antisense oligonucleotide designed to target the tau protein. Biogen secured the rights to diranersen through an exclusive licensing agreement with Ionis Pharmaceuticals in 2019. Ionis, a pioneer in ASO technology, engineered diranersen to reduce the production of tau protein and inhibit its abnormal accumulation, both within neurons (intra-cellular) and in the extracellular space.
In a healthy brain, tau is a crucial protein that plays a vital role in stabilizing microtubules, essential components of the neuronal cytoskeleton, and facilitating the transport of nutrients along axons. However, in Alzheimer’s disease, tau undergoes abnormal modifications, leading to its aggregation into neurofibrillary tangles. These tangles are considered a hallmark pathology of the disease and are strongly correlated with neurodegeneration and the progressive cognitive decline experienced by patients. By targeting and reducing the accumulation of pathological tau, diranersen aims to interrupt this destructive cascade, thereby potentially slowing or halting disease progression.
Priya Singhal, Biogen’s Executive Vice President and Head of Development, expressed strong belief in diranersen’s potential, stating that the therapy has achieved "an unprecedented and compelling confluence of efficacy and biomarker results." This statement underscores Biogen’s strategic focus on diranersen as a key asset in its Alzheimer’s pipeline, particularly given the limitations and challenges faced by other therapeutic approaches.
The Path Forward: Lessons Learned and Future Expectations
The decision to advance diranersen to Phase III is not without its complexities. Biogen’s previous experience with Aduhelm (aducanumab), an anti-amyloid therapy that received accelerated approval based on biomarker data but ultimately faced significant commercial challenges due to questions about its clinical benefit and safety, serves as a cautionary tale. As Philippa Salter of GlobalData points out, Biogen "must also prove they have learned from their experience developing Aduhelm." This implies a need for robust, clinically meaningful data from the Phase III trials that unequivocally demonstrate a tangible benefit for patients.
The upcoming Phase III program will be critical in validating the promising biomarker data and the observed slowing of cognitive decline. These larger-scale studies will aim to provide definitive evidence of diranersen’s efficacy and safety in a broader patient population, thereby building the necessary confidence for regulatory approval and eventual market adoption.
The Alzheimer’s research community will be keenly awaiting the full data readout at AAIC 2026. This event is expected to shed further light on diranersen’s therapeutic potential and its role in the evolving landscape of Alzheimer’s disease treatment. The success of diranersen could represent a significant advancement in targeting tau pathology, offering a new avenue of hope for millions affected by this devastating neurodegenerative condition. The focus now shifts to designing and executing the Phase III trials with the highest scientific rigor, aiming to translate the promising early signals into a tangible benefit for patients.
About the Author
